Literature DB >> 16973603

Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast.

Benjamin Dehay1, Anne Bertolotti.   

Abstract

Nine neurodegenerative diseases, such as Huntington, are caused by a polyglutamine (poly(Q)) expansion in otherwise unrelated proteins. Although poly(Q) expansion causes aggregation of the affected proteins, the protein context might determine the selective neuronal vulnerability found in each disease. Here we have report that, although expression of Huntingtin derivatives with a pathological poly(Q) expansion are innocuous in yeast, deletion of the flanking proline-rich region alters the shape and number of poly(Q) inclusions and unmasks toxic properties. Strikingly, deletion of Hsp104 increases the size of inclusions formed by expanded poly(Q) lacking the proline-rich region and abolishes toxicity. Overexpression of the chaperones Hsp104 or Hsp70 rescues growth defects in affected cells without resolving inclusions. However, aggregates formed by nontoxic Huntingtin derivatives or by toxic derivatives cured by chaperones are physically distinct from aggregates formed by toxic proteins. This study identifies the proline-rich region in Huntingtin as a profound cis-acting modulator of expanded poly(Q) toxicity and distinguishes between aggregates of toxic or non-toxic proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973603     DOI: 10.1074/jbc.M605558200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

Review 1.  Polyglutamine misfolding in yeast: toxic and protective aggregation.

Authors:  Martin L Duennwald
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

Review 2.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

3.  Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.

Authors:  Mingchen Chen; Peter G Wolynes
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-11       Impact factor: 11.205

4.  Dynamic interactions of Sup35p and PrP prion protein domains modulate aggregate nucleation and seeding.

Authors:  Carmen Krammer; Elisabeth Kremmer; Hermann M Schätzl; Ina Vorberg
Journal:  Prion       Date:  2008 Jul-Sep       Impact factor: 3.931

5.  Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery.

Authors:  Yan Wang; Anatoli B Meriin; Nava Zaarur; Nina V Romanova; Yury O Chernoff; Catherine E Costello; Michael Y Sherman
Journal:  FASEB J       Date:  2008-10-14       Impact factor: 5.191

Review 6.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

Review 7.  Defining the limits: Protein aggregation and toxicity in vivo.

Authors:  William M Holmes; Courtney L Klaips; Tricia R Serio
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-04-28       Impact factor: 8.250

8.  Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences.

Authors:  Vinal V Lakhani; Feng Ding; Nikolay V Dokholyan
Journal:  PLoS Comput Biol       Date:  2010-04-29       Impact factor: 4.475

9.  The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation.

Authors:  Stephen Tam; Christoph Spiess; William Auyeung; Lukasz Joachimiak; Bryan Chen; Michelle A Poirier; Judith Frydman
Journal:  Nat Struct Mol Biol       Date:  2009-11-15       Impact factor: 15.369

10.  Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones.

Authors:  Erwann Rousseau; Rieko Kojima; Guylaine Hoffner; Philippe Djian; Anne Bertolotti
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.